| Disitamab Vedotin studied in …STUDIED_INderived60 of 60show fewer |
|---|
| → studied in | NCT07498907Phase 3 · recruiting Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma · 60 trials list this drug (47 active) | — | — | Renal Pelvis and Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07315750Phase 3 · recruiting A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. · 60 trials list this drug (47 active) | — | — | Gastric Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730373Phase 2 · recruiting First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · 60 trials list this drug (47 active) | — | — | Malignant Gastric Neoplasm,Gastric Carcinoma,HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966453Phase 1/Phase 2 · active not recruiting A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer · 60 trials list this drug (47 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649331Phase 2 · recruiting Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07756008Phase 2/Phase 3 · not yet recruiting Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer · 60 trials list this drug (47 active) | — | — | Bladder Neoplasm,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740993Phase 2 · not yet recruiting A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma · 60 trials list this drug (47 active) | — | — | Sebaceous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04879329Phase 2 · recruiting A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 · 60 trials list this drug (47 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05911295Phase 3 · active not recruiting Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 · 60 trials list this drug (47 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06003231Phase 2 · active not recruiting A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 · 60 trials list this drug (47 active) | — | — | Head and Neck Neoplasm,Ovarian Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06157892Phase 2 · active not recruiting A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors · 60 trials list this drug (47 active) | — | — | Breast Neoplasm,Gastric Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717242Phase 2 · recruiting Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer · 60 trials list this drug (47 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06187506Phase 2 · active not recruiting Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07646145Phase 2 · recruiting Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer · 60 trials list this drug (47 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07608224Phase 2/Phase 3 · not yet recruiting HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC · 60 trials list this drug (47 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07591805Phase 2 · not yet recruiting HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC · 60 trials list this drug (47 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05831878NA · recruiting RC48-ADC in HER2-low Advanced Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07474064Phase 2 · not yet recruiting Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07474324Phase 2 · recruiting Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07446452Phase 2 · recruiting Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study · 60 trials list this drug (47 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07366840Phase 2/Phase 3 · not yet recruiting RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06210490Phase 2 · recruiting A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery · 60 trials list this drug (47 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06178159Phase 2 · recruiting DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07194005Phase 2 · recruiting Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer · 60 trials list this drug (47 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05851677recruiting Disitamab Vedotin (RC48-ADC) in Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07172217Phase 2 · not yet recruiting The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC · 60 trials list this drug (47 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07159217Phase 2 · not yet recruiting Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer · 60 trials list this drug (47 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07142200Phase 2 · not yet recruiting A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07065435Phase 2 · recruiting RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study · 60 trials list this drug (47 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06957561Phase 1/Phase 2 · not yet recruiting Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer · 60 trials list this drug (47 active) | — | — | Bladder Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904573Phase 2 · recruiting Probiotics in Advanced Urothelial Carcinoma · 60 trials list this drug (47 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06642545Phase 2 · recruiting Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05586061Phase 2 · active not recruiting First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer · 60 trials list this drug (47 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561555Phase 2 · recruiting A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease. · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06663007Phase 1/Phase 2 · recruiting RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · 60 trials list this drug (47 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06650332Phase 1/Phase 2 · recruiting Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06105008Phase 2 · withdrawn Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer · 60 trials list this drug (47 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06378242Phase 1/Phase 2 · recruiting To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06492317Phase 2 · not yet recruiting RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer · 60 trials list this drug (47 active) | — | — | HER2-Positive Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06227156Phase 2 · unknown Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer · 60 trials list this drug (47 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06389006Phase 2 · recruiting To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385873Phase 2 · not yet recruiting RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer · 60 trials list this drug (47 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06233864Phase 2 · unknown A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer · 60 trials list this drug (47 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06221748Phase 2/Phase 3 · recruiting DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy · 60 trials list this drug (47 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06155396Phase 2 · recruiting A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer · 60 trials list this drug (47 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06278870Phase 3 · recruiting Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06185400Phase 2 · not yet recruiting RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations · 60 trials list this drug (47 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04311034Phase 1/Phase 2 · completed A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer · 60 trials list this drug (47 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06155383Phase 2 · recruiting Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. · 60 trials list this drug (47 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05940896Phase 1 · recruiting RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression · 60 trials list this drug (47 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06078982Phase 1 · unknown Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer · 60 trials list this drug (47 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05957757Phase 2 · unknown RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05904964Phase 3 · recruiting Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) · 60 trials list this drug (47 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05912205Phase 2 · unknown Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation · 60 trials list this drug (47 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05726175Phase 2 · unknown Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer · 60 trials list this drug (47 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05649163unknown Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy · 60 trials list this drug (47 active) | — | — | Solid Neoplasm,Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627414Phase 2 · unknown Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer · 60 trials list this drug (47 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05493683Phase 2 · unknown Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer · 60 trials list this drug (47 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05495724Phase 2 · unknown Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable · 60 trials list this drug (47 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05333809Phase 2 · unknown Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer · 60 trials list this drug (47 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |